Key findings
- 90CGG repeats in the patient’s FMR1 gene, a premutation, which established the molecular diagnosis of FXTAS
- 0.28Evans index, described as slightly elevated but not the definite ventricular enlargement expected in NPH; the callosal angle was normal and there was no DESH
- 110/60 mmHgstanding blood pressure, below the supine reading: orthostatic hypotension, one of the findings that pointed beyond NPH
- >200CGG repeats, a full FMR1 mutation, in a grandson with autism spectrum disorder
Abstract
- Background
- Fragile X-associated tremor/ataxia syndrome (FXTAS) is a late-onset neurodegenerative disorder affecting carriers of an FMR1 premutation. Its manifestations, including gait disturbance, cognitive impairment, urinary dysfunction, parkinsonism, and ventriculomegaly, may overlap with normal-pressure hydrocephalus (NPH), potentially leading to inappropriate invasive treatment.
- Case presentation
- A 75-year-old Arab man with long-standing diabetes initially developed bilateral upper-limb tremor, followed by progressive gait ataxia, urinary incontinence, and cognitive decline. Computed tomography demonstrated ventriculomegaly, prompting referral for consideration of ventriculoperitoneal shunting for presumed NPH. Neurological examination, however, demonstrated orthostatic hypotension, executive and cognitive dysfunction, symmetric rigidity and bradykinesia, postural instability, bilateral upper-limb ataxia, and intention tremor. Brain magnetic resonance imaging showed cerebral and cerebellar atrophy with ventriculomegaly and T2/FLAIR hyperintensities involving the periventricular white matter, corpus callosum, bilateral middle cerebellar peduncles, and cerebellar white matter adjacent to the dentate nuclei. The characteristic middle cerebellar peduncle sign and splenium sign together with the clinical phenotype, raised suspicion for FXTAS. Molecular testing demonstrated an FMR1 premutation with 90 CGG repeats. Subsequent family evaluation revealed a grandson with autism spectrum disorder who carried a full FMR1 mutation (>200 CGG repeats). These findings established the diagnosis of FXTAS and prompted genetic counseling of the family.
- Conclusion
- FXTAS should be considered in older adults presenting with an NPH-like phenotype, particularly when intention tremor, cerebellar ataxia, parkinsonism, autonomic dysfunction, or characteristic white-matter abnormalities accompany ventriculomegaly. Recognition of these clinical and radiological clues can prompt appropriate FMR1 testing and may prevent unnecessary CSF diversion procedures.
Introduction
Normal pressure hydrocephalus (NPH) is a relatively common cause of treatable dementia in elderly, where patients present with triad of gait disturbances, urinary incontinence and dementia and imaging shows ventriculomegaly.1 NPH is sometimes classified into idiopathic (iNPH) and secondary (sNPH), resulting from subarachnoid hemorrhage, meningitis, intracerebral hemorrhage, brain tumor or head trauma.2 However NPH has been almost indiscriminately used for all individuals who present with “unexplained” ventriculomegaly detected by brain imaging including computed tomography (CT) or magnetic resonance imaging (MRI), associated with the classic triad comprising cognitive impairment, gait disturbance, and incontinence.3,4 Since these clinical features are not uncommon in elderly population, it is recommended to consider conditions such as Alzheimer’s disease (AD), atypical Parkinsonism, dementia with Lewy bodies (DLB), progressive supranuclear palsy (PSP), and vascular dementia (VaD), in patients presenting with similar symptoms to avoid inappropriate treatment.5
Fragile X tremor ataxia syndrome is an inherited disorder with no definite cure.6 It usually presents in the sixth decade of life. FXTAS presents commonly with intention tremor and/or ataxia, with lower extremity neuropathy, autonomic dysfunction, and gradual cognitive decline. It occurs in individuals with premutation FMR1 alleles. While the symptoms of FXTAS vary among individuals, almost all affected persons develop problematic cerebellar gait ataxia as the disorder progresses. Psychiatric features, including anxiety, disinhibition, depression, and apathy, are also common problems.7 Due to the overlap of symptoms patients with FXYAs are frequently misdiagnosed as Parkinsonism, dementia, cerebellar ataxia, multiple sclerosis, peripheral neuropathy or NPH.9
Since the presenting symptoms including gait disturbances, cognitive dysfunction, urinary disturbances and ventriculomegaly are common in FXTAS and NPH, it is easily mistaken for NPH, since the latter being much more prevalent.
The MRI features of FXTAS include global brain atrophy; white matter disease in the subcortical, middle cerebellar peduncle (MCP), and periventricular regions; and dilated ventricles.10,11. Thorough family history evaluation, MRI brain and genetic screening helps to precisely diagnose the condition early
Case presentation
A 75 year old Arab gentleman with history of long-standing diabetes initially presented with postural tremor of bilateral hands, which was considered as essential tremor in view of positive family history of essential tremor in his family. Over the next two years, he started having progressive gait ataxia, urinary incontinence and progressive dementia.
He was seen by internal medicine team; CT brain was done which showed ventriculomegaly. He was referred to Neurosurgery with a provisional diagnosis of NPH for considering CSF diversion procedure. The neurosurgery team referred to Neurology to determine candidacy for Ventriculoperitoneal shunt.
Clinical examination revealed orthostatic hypotension. Supine blood pressure was 150/70mmHg, while BP recorded in standing position was 110/60 mmHg. Neurological examination revealed cognitive disturbances with Montreal Cognitive Assessment (MoCA) score of 18/30, losing points in attention, execution, recall and naming. He had symmetric rigidity and bradykinesia, postural instability and bilateral upper limb ataxia and intention tremors.
Diagnosis and management
Nerve conduction studies demonstrated an axonal sensorimotor polyneuropathy. Brain MRI showed cerebral and cerebellar atrophy with ventriculomegaly. Periventricular T2/FLAIR hyperintensities had initially been attributed to chronic small-vessel ischemic change in view of the patient's vascular risk factors. The calculated Evan’s index was 0.28, Callosal angle was 105o and there was no disproportionately enlarged subarachnoid-space hydrocephalus (DESH). On further review, however, additional symmetrical T2/FLAIR hyperintensities were identified in the bilateral middle cerebellar peduncles, corpus callosum, and cerebellar white matter adjacent to the dentate nuclei. The bilateral MCP hyperintensity (“MCP sign”) and splenial hyperintensity in combination with the clinical phenotype characterized by combination of late-onset intention tremor, cerebellar ataxia, parkinsonism, cognitive impairment, autonomic dysfunction, peripheral neuropathy raised a strong suspicion of FXTAS and prompted molecular testing of the FMR1 gene. Genetic testing by Polymerase Chain Reaction with Capillary Electrophoresis identified an FMR1 premutation containing 90 CGG repeats, establishing the molecular diagnosis of FXTAS.
A detailed family history was obtained. His parents were distant relatives. Patient had four sons and three daughters, He had 12 grand children from his sons (4 males and 8 females) and 5 grand children from his two daughters (three female and two males) , one daughter was un married. One of the daughter’s son had history of autism spectrum disorder with intellectual disability. Genetic testing in the grandson demonstrated a full FMR1 mutation (>200 CGG repeats). Genetic counseling was recommended for the family.
The patient fulfilled criteria for definite FXTAS, based on the presence of an FMR1 premutation together with major clinical features of intention tremor and gait ataxia and the major radiological feature of bilateral MCP white-matter hyperintensity.
The patient was discussed in multidisciplinary team meeting including internal medical team, neurology team, neurosurgery team radiology teams and clinical genetist. A slightly high Evans index raised a possible suggestion of NPH, but a normal callosal angle and absence of DESH and definite alternative diagnosis argued against the diagnosis of NPH. Also, cognitive dysfunction with cortical features prompted us to consider a diagnosis of NPH unlikely
Rivastigmine patch was initiated for symptomatic treatment of cognitive impairment. Fludrocortisone was prescribed for symptomatic orthostatic hypotension. Beta-blockers and dopaminergic therapy were avoided because of significant orthostatic hypotension. Despite symptomatic treatment, his neurological impairment continued to progress. Genetic counseling was recommended for the patient and his family.
Discussion
This case illustrates an important diagnostic overlap between FXTAS and NPH in older adults resulting in referral for consideration of ventriculoperitoneal shunting.12. However, several additional findings, particularly intention tremor, appendicular ataxia, parkinsonism, peripheral neuropathy, orthostatic hypotension, and the characteristic MCP sign, suggested a broader neurodegenerative disorder and prompted evaluation for FXTAS.14,15
The distinction between NPH and neurodegenerative disorders presenting with ventriculomegaly can be challenging, particularly in older patients in whom gait impairment, cognitive decline, and urinary symptoms are relatively nonspecific. Current diagnostic criteria for idiopathic NPH emphasize that clinical symptoms should not be completely explained by another neurological or non-neurological disorder.12,13 Ventriculomegaly alone is insufficient to establish the diagnosis. Although an Evans index greater than 0.3 is commonly used to define ventricular enlargement, this finding is not specific for NPH.12,17 Additional imaging features, including disproportionately enlarged subarachnoid-space hydrocephalus (DESH), narrowing of the high-convexity subarachnoid spaces, enlargement of the Sylvian fissures, and a reduced callosal angle, can strengthen the diagnosis of idiopathic NPH and help distinguish hydrocephalus from ventricular enlargement related to cerebral atrophy.12,17 Our patient had a slightly elevated Evan’s index of 0.28, which did not suggest a definite ventricular enlargement as expected in NPH, Also the callosal angle was normal and there was no evidence of disproportionately enlarged subarachnoid-space hydrocephalus (DESH).This was particularly relevant in our patient. His combination of gait dysfunction, cognitive impairment, urinary incontinence, and ventriculomegaly initially supported consideration of NPH. However, the neurological examination demonstrated abnormalities that were difficult to attribute to isolated NPH. Intention tremor and appendicular cerebellar ataxia are major clinical manifestations of FXTAS, while parkinsonism, executive dysfunction, peripheral neuropathy, and autonomic dysfunction are also well-recognized components of its neurological phenotype.14,15 The coexistence of cerebellar, extrapyramidal, peripheral neurological, cognitive, and autonomic abnormalities therefore provided an important indication that the patient's syndrome extended beyond the conventional NPH phenotype.
Autonomic dysfunction is particularly relevant to the clinical overlap between the two disorders. Urinary incontinence is a characteristic component of the NPH clinical syndrome but can also occur in FXTAS as part of autonomic nervous system involvement .18 Orthostatic hypotension, as demonstrated in our patient, provides an additional clue to more widespread autonomic dysfunction and is recognized in FXTAS.18 Similarly, peripheral neuropathy is an established manifestation of FXTAS, and electrophysiological studies have described a predominantly axonal sensorimotor polyneuropathy.18 In our patient, nerve conduction studies demonstrated an axonal sensorimotor neuropathy. However, this finding must be interpreted cautiously because his long-standing diabetes mellitus represents an important alternative explanation for both peripheral neuropathy and autonomic dysfunction. These manifestations therefore cannot be attributed exclusively to FXTAS. Nevertheless, diabetes would not adequately explain the progressive cerebellar syndrome, parkinsonian features, characteristic MRI abnormalities, and FMR1 premutation identified in this patient.
Presence of autonomic dysfunction and parkinsonism with cerebellar signs raised a possibility of Multiple System atrophy(MSA), however significant cognitive dysfunction made this diagnosis unlikely, also the presence of MCP sign instead of pontine and middle cerebellar atrophy ruled out the possibility of MSA.19
Neuroimaging provided the most important clue that redirected the diagnostic evaluation. Bilateral T2/FLAIR hyperintensity involving the middle cerebellar peduncles, commonly referred to as the MCP sign, is the best-recognized neuroimaging feature of FXTAS and represents a major radiological diagnostic criterion 15 The MCP sign has been reported in approximately 58% to 82% of affected males, although it is not completely specific to FXTAS. Other recognized MRI abnormalities include T2/FLAIR hyperintensities involving the splenium of the corpus callosum (splenium sign) , cerebral and periventricular white matter, and brainstem, together with generalized cerebral and cerebellar atrophy 15
The imaging findings in our patient demonstrate the importance of considering the distribution of white-matter abnormalities rather than interpreting individual abnormalities in isolation. His periventricular T2/FLAIR hyperintensities were initially considered to represent leukoaraiosis in the context of age and vascular risk factors. However, further review demonstrated bilateral MCP involvement, abnormalities of the corpus callosum, and cerebellar white-matter changes adjacent to the dentate nuclei. In combination with intention tremor, cerebellar ataxia, cognitive dysfunction, and parkinsonism, this distribution raised suspicion for FXTAS and prompted molecular testing.
Ventricular enlargement itself is also increasingly recognized within the neuroimaging spectrum of advanced FXTAS. Progressive cerebral white-matter disease and cerebral volume loss can be associated with substantial enlargement of the lateral ventricles, and some patients with FXTAS may reach radiological criteria used for NPH.19 This observation provides a plausible explanation for why FXTAS can produce an NPH-like clinical and radiological phenotype. Importantly, the presence of ventriculomegaly in FXTAS should not automatically be interpreted as evidence of a second diagnosis of NPH. Conversely, identification of FXTAS does not completely exclude concomitant NPH. The clinical context, morphology of ventricular enlargement, features of DESH, callosal angle, and, where appropriate, response to CSF drainage should therefore be considered before deciding whether CSF diversion is indicated.12
The molecular findings provided confirmation of the underlying disorder. FXTAS occurs primarily in carriers of an FMR1 premutation, generally defined by the presence of approximately 55 to 200 CGG repeats.14 Our patient had 90 CGG repeats, placing him within the premutation range. In the presence of an FMR1 premutation, his intention tremor and cerebellar gait ataxia represented major clinical features, while the bilateral MCP white-matter abnormality and splenial hyperintensity represented a major radiological feature. Taken together, these findings fulfill established criteria for definite FXTAS.14,15,17 The additional presence of parkinsonism, peripheral neuropathy, executive and cognitive dysfunction, and generalized cerebral and cerebellar atrophy further supported the diagnosis.
The family history added an important genetic dimension to the case. Subsequent evaluation identified a grandson with autism spectrum disorder who was found to carry a full FMR1 mutation with more than 200 CGG repeats. The distinction between the premutation identified in the proband and the full mutation identified in the grandson is important. Male premutation carriers transmit their FMR1 premutation to all daughters but not to their sons, while expansion from a premutation to a full mutation occurs through maternal transmission.3 Therefore, clarification of the intervening maternal carrier status is important for appropriate interpretation of the pedigree and for genetic counseling. The recognition of FXTAS in an older individual can consequently have implications extending beyond the affected patient and may identify other family members at risk of FMR1-associated disorders.
Another important feature of this case is the potential for diagnostic anchoring. The combination of the classic clinical triad and ventriculomegaly naturally raised the possibility of NPH, particularly because NPH represents a potentially treatable neurological condition. However, the diagnosis of idiopathic NPH requires more than recognition of ventricular enlargement in an older patient with gait and cognitive symptoms.12. A detailed neurological examination remains essential. Findings such as prominent intention tremor, appendicular cerebellar ataxia, peripheral neuropathy, marked autonomic dysfunction, or neurological abnormalities that cannot be adequately explained by NPH should prompt consideration of alternative or coexisting neurological disorders. In appropriate patients, characteristic MRI abnormalities should lead to targeted FMR1 molecular testing before an invasive intervention is pursued.
The distinction has practical therapeutic implications. CSF diversion can improve symptoms in appropriately selected patients with idiopathic NPH, particularly gait dysfunction.12,13 In contrast, there is currently no disease-modifying treatment for FXTAS, and management is predominantly symptomatic.14,18 Although substantial ventricular enlargement has been described in advanced FXTAS, current literature does not provide evidence that shunting patients whose ventricular enlargement is attributable to FXTAS improves the underlying neurological syndrome.18 Accurate characterization of the cause of ventriculomegaly is therefore important before exposing a patient to an invasive procedure and its associated risks.
Our case also highlights the value of multidisciplinary assessment. The patient initially came to medical attention because of symptoms compatible with NPH and was appropriately referred for neurosurgical assessment. Subsequent neurological examination and detailed review of the MRI identified findings that changed the diagnostic direction, while molecular testing established the underlying genetic disorder. The case therefore illustrates how integration of clinical examination, neuroimaging, and molecular genetics can prevent premature attribution of a complex neurological syndrome to a single common diagnosis.
This case emphasizes that FXTAS should be considered in the differential diagnosis of older adults presenting with an NPH-like syndrome, particularly when ventriculomegaly is accompanied by intention tremor, cerebellar ataxia, parkinsonism, peripheral neuropathy, autonomic dysfunction, or characteristic MCP and corpus callosal abnormalities. Recognition of this phenotype can direct appropriate FMR1 testing, inform decisions regarding CSF diversion, and identify families who may benefit from genetic counseling.
Conclusion
FXTAS should be considered in older adults presenting with gait impairment, cognitive decline, urinary dysfunction, and ventriculomegaly when additional neurological features such as intention tremor, cerebellar ataxia, parkinsonism, peripheral neuropathy, or autonomic dysfunction are present. Recognition of characteristic MRI abnormalities, particularly the MCP sign and splenium sign should prompt FMR1 molecular testing and careful assessment of the family history. Distinguishing an FXTAS-related NPH-like phenotype from true NPH is clinically important because it may prevent inappropriate CSF diversion and facilitate genetic counseling of affected families
Declarations
- Consent Statement
- Patient’s eldest son who is the primary caretaker of the patient, consented to publication
References
- Hakim S, Adams RD. The special clinical problem of symptomatic hydrocephalus with normal cerebrospinal fluid pressure. Observations on cerebrospinal fluid hydrodynamics. J Neurol Sci. 1965;2:307-27
- Bradley WG. Normal pressure hydrocephalus: new concepts on etiology and diagnosis. AJNR Am J Neuroradiol. 2000;21:1586-90.
- Espay A, Da Prat G, Dwivedi A, Rodriguez-Porcel F, Vaughan J, Rosso M, et al. Deconstructing normal pressure hydrocephalus: Ventriculomegaly as early sign of neurodegeneration. Ann Neurol 2017;82(4):503-13.
- Hebb AO, Cusimano MD. Idiopathic normal pressure hydrocephalus: a systematic review of diagnosis and outcome. Neurosurgery. 2001;49: 1166-86
- Kiefer M, Unterberg A. The Differential Diagnosis and Treatment of Normal-Pressure Hydrocephalus. Dtsch Arztebl Int. 2012;109(1-2):15-25
- Amiri K, Hagerman RJ, Hagerman PJ. Fragile X–Associated Tremor/Ataxia Syndrome: An Aging Face of the Fragile X Gene. Arch Neurol. 2008;65(1):19–25. doi:10.1001/archneurol.2007.30
- Leehey MA. Fragile X-associated tremor/ataxia syndrome: clinical phenotype, diagnosis, and treatment. J Investig Med. 2009 Dec;57(8):830-6. doi: 10.2310/JIM.0b013e3181af59c4. PMID: 19574929; PMCID: PMC2787702.
- Hagerman RJLeehey MHeinrichs W et al. Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology 2001;57 (1) 127- 130
- Hall DA, Berry-Kravis E, Jacquemont S, Rice CD, Cogswell J, Zhang L, Hagerman RJ, Hagerman PJ, Leehey MA. Initial diagnoses given to persons with the fragile X associated tremor/ataxia syndrome (FXTAS). Neurology. 2005 Jul 26;65(2):299-301. doi: 10.1212/01.wnl.0000168900.86323.9c. Erratum in: Neurology. 2005 Sep 13;65(5):784. PMID: 16043804.
- Cohen SMasyn KAdams J et al. Molecular and imaging correlates of the fragile X-associated tremor/ataxia syndrome. Neurology 2006;67 (8) 1426- 1431
- Leehey MAHagerman RJLandau WMGrigsby JTassone FHagerman PJ A tremor/ataxia syndrome in fragile X carrier males. Mov Disord 2002;17 (4) 744- 745
- Nakajima M, Yamada S, Miyajima M, Ishii K, Kuriyama N, Kazui H, et al. Guidelines for management of idiopathic normal pressure hydrocephalus (third edition): endorsed by the Japanese Society of Normal Pressure Hydrocephalus. Neurol Med Chir (Tokyo). 2021;61(2):63-97. doi:10.2176/nmc.st.2020-0292.
- Passos-Neto CEB, Lopes CCB, Teixeira MS, Studart Neto A, Spera RR. Normal pressure hydrocephalus: an update. Arq Neuropsiquiatr. 2022;80(5 Suppl 1):42-52. doi:10.1590/0004-282X-ANP-2022-S118.
- Hunter JE, Berry-Kravis E, Hipp H, Todd PK. FMR1 disorders. In: Adam MP, Bick S, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2026. 1998 Jun 16 [updated 2024 May 16].
- Hagerman RJ, Hagerman P. Fragile X-associated tremor/ataxia syndrome: pathophysiology and clinical implications. Mov Disord. 2021;36(2):317-327. doi:10.1002/mds.28358. PMID: 32575683.
- Famula JL, McKenzie F, McLennan YA, Grigsby J, Tassone F, Hessl D, et al. Presence of middle cerebellar peduncle sign in FMR1 premutation carriers without tremor and ataxia. Front Neurol. 2018;9:695. doi:10.3389/fneur.2018.00695.
- Leehey MA. Fragile X-associated tremor/ataxia syndrome: clinical phenotype, diagnosis, and treatment. J Investig Med. 2009;57(8):830-836. doi:10.2310/JIM.0b013e3181af59c4.
- Hagerman R, Hagerman P. Fragile X-associated tremor/ataxia syndrome: pathophysiology and management. Curr Opin Neurol. 2021;34(4):541-546. doi:10.1097/WCO.0000000000000954.
- Wenning, G.K., Stankovic, I., Vignatelli, L., Fanciulli, A., Calandra-Buonaura, G., Seppi, K., Palma, J.-A., Meissner, W.G., Krismer, F., Berg, D., Cortelli, P., Freeman, R., Halliday, G., Höglinger, G., Lang, A., Ling, H., Litvan, I., Low, P., Miki, Y., Panicker, J., Pellecchia, M.T., Quinn, N., Sakakibara, R., Stamelou, M., Tolosa, E., Tsuji, S., Warner, T., Poewe, W. and Kaufmann, H. (2022), The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy. Mov Disord, 37: 1131-1148.
Article information
Authors
- Pournamy SarathchandranDepartment of Neurology, Al Qassimi hospital, Sharjah
- Ahlam AlmarzooqiDepartment of Internal Medicine, Al Qassimi hospital, Sharjah
- Abdulmoen AbdulkarimDepartment of Internal Medicine, Al Qassimi hospital, Sharjah
- Muaz ElSayedDepartment of Neurology, Al Qassimi hospital, Sharjah
- Ajith Kumar BVDepartment of Internal Medicine, Al Qassimi hospital, Sharjah
- Maged Abdulla FamDepartment of Radiology, Al Qassimi hospital, Sharjah
How to cite
Sarathchandran, P., Almarzooqi, A., et al., 2026. Fragile X-Associated Tremor/Ataxia Syndrome Mimicking Normal-Pressure Hydrocephalus: Clinical, Neuroimaging, and Genetic Clues to the Diagnosis. Medical Research Archives, [online] 14(10). https://doi.org/10.18103/mra.2026.0688
Record
- Journal
- Medical Research Archives
- Issue
- Vol 14 No 10 (2026)
- Section
- Case Reports
- Published
- 31 October 2026
- ISSN
- 2375-1924
- Downloads
- 80
Copyright and licence
Published by the European Society of Medicine under a Creative Commons Attribution 4.0 International licence (CC BY 4.0), which permits unrestricted use, distribution and reproduction in any medium, provided the original authors and source are credited.